Compare GSK plc (GSK) vs Prudential Financial Inc (PRU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs Prudential Financial Inc — how do they compare? GSK plc trades at $46.65 (market cap $91.88B), while Prudential Financial Inc trades at $112.95 (market cap $39.17B). The key difference: GSK plc is far larger — about 2.3× Prudential Financial Inc's market cap, and Prudential Financial Inc pays the higher dividend (4.93%). Which is the better fit depends on your goals — on Pluang, investors hold GSK plc for 93 Days and Prudential Financial Inc for 145 Days on average.
| GSK | PRU | |
|---|---|---|
Market Cap | $91.88B | $39.17B |
Volume | 7,730,529 | 1,436,917 |
Sector | Health | Financials |
52-Week High | $61.18 | $125.13 |
52-Week Low | $43.24 | $92.00 |
Typical Hold Time | 93 Days | 145 Days |
Enterprise Value | $111.88B | $67.95B |
Dividend Yield | 3.9% | 4.93% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK trades at $46.45, down 1.21% with bearish technical signals. The company shows strong fundamentals with revenue growth to $32.67B in 2025 and consistent earnings beats. Valuation metrics appear reasonable with P/E of 14.89 and EV/EBITDA of 8.75. Recent developments include strategic oncology partnerships and a $750M cancer therapy acquisition, positioning for long-term growth despite near-term technical weakness.
GSK presents a mixed outlook with strong profitability and pipeline expansion offset by technical bearishness and HIV patent concerns. The company's 29.73% ROE and recent earnings outperformance support investment appeal, while the bearish moving average signal and competitive pressures warrant caution. Analyst consensus leans hold with 55% neutral rating, suggesting balanced risk-reward for long-term investors.
Prudential Financial (PRU) trades at $112.97, up 0.54% with a bearish technical signal despite recent earnings beats. The stock shows attractive valuation metrics with P/E of 10.29 and P/S of 0.61, while maintaining solid profitability with 6.04% net margin and 12.46% ROE. Recent strategic moves include the Alexforbes stake sale and rebranding to Prudential Wealth Advisors, reflecting focus on core operations.
While PRU offers value appeal through strong fundamentals and dividend yield, investors face headwinds from bearish technicals and mixed analyst sentiment. The company's capital rotation strategy and PGIM growth initiatives provide upside potential, but execution risks and market volatility remain concerns. Current price sits above consensus target of $105.67, suggesting limited near-term upside.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About Prudential Financial Inc
Prudential Financial is a large, diversified insurance company offering annuities, life insurance, retirement plan services, and asset management products. While it operates in a number of countries, the vast majority of revenue is generated in the United States and Japan. The company's investment management business, PGIM, contributes approximately 15% of its earnings and has over $1.5 trillion in assets under management. The U.S. businesses are responsible for about 45% of earnings and can be classified into Institutional Retirement Strategies, Individual Retirement Strategies, Group Insurance, Individual Life Insurance, and Assurance IQ. Finally, the international business segment of the company contributes approximately 40% of earnings with a strong market position in Japan.
Read more on PRU →
